- Home
- LSBK vs CUE Comparison
LSBK vs CUE Comparison
Compare LSBK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- CUE
- Stock Information
- Founded
- LSBK 1891
- CUE 2014
- Country
- LSBK United States
- CUE United States
- Employees
- LSBK N/A
- CUE N/A
- Industry
- LSBK Savings Institutions
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- CUE Health Care
- Exchange
- LSBK Nasdaq
- CUE Nasdaq
- Market Cap
- LSBK 90.0M
- CUE 48.0M
- IPO Year
- LSBK 2006
- CUE 2018
- Fundamental
- Price
- LSBK $15.85
- CUE $0.74
- Analyst Decision
- LSBK
- CUE Strong Buy
- Analyst Count
- LSBK 0
- CUE 3
- Target Price
- LSBK N/A
- CUE $3.00
- AVG Volume (30 Days)
- LSBK 6.0K
- CUE 323.3K
- Earning Date
- LSBK 07-23-2025
- CUE 08-13-2025
- Dividend Yield
- LSBK 3.39%
- CUE N/A
- EPS Growth
- LSBK 27.62
- CUE N/A
- EPS
- LSBK 0.89
- CUE N/A
- Revenue
- LSBK $25,795,000.00
- CUE $7,991,000.00
- Revenue This Year
- LSBK N/A
- CUE N/A
- Revenue Next Year
- LSBK N/A
- CUE $23.84
- P/E Ratio
- LSBK $17.83
- CUE N/A
- Revenue Growth
- LSBK N/A
- CUE 13.83
- 52 Week Low
- LSBK $11.85
- CUE $0.45
- 52 Week High
- LSBK $16.95
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- LSBK 50.07
- CUE 51.10
- Support Level
- LSBK $15.22
- CUE $0.65
- Resistance Level
- LSBK $16.20
- CUE $0.83
- Average True Range (ATR)
- LSBK 0.15
- CUE 0.07
- MACD
- LSBK -0.02
- CUE 0.01
- Stochastic Oscillator
- LSBK 55.11
- CUE 30.43
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.